Involvement of the Innate Immune System in the Pathogenesis of Chronic Obstructive Pulmonary Disease

Kotlyarov, Stanislav

doi:10.3390/ijms23020985

Cited by 22 publications

(23 citation statements)

References 190 publications

(234 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Increasing evidence suggests that the progression of COPD may be related to the occurrence of autoimmunity in the lungs [9] . Indeed, mechanisms underlying the innate immune system have been implicated in the pathogenesis of COPD, and may lead to the persistence of chronic in ammation in the bronchi [10] . Therefore, only using in ammatory or immune markers to assess the prognosis of COPD patients may not be effective.…”

Section: Introductionmentioning

confidence: 99%

WITHDRAWN: Relationship between NMLR and all-cause mortality in patients with chronic obstructive pulmonary disease: National Health and Nutrition Examination Survey, 1999–2018

Lü

Zhu

Xiao

et al. 2022

Preprint

View full text Add to dashboard Cite

Background Chronic obstructive pulmonary disease (COPD) has one of the highest morbidity and mortality rates worldwide. COPD-related deaths are associated with inflammation and immunity. As one of the emerging indicators of inflammation and immune status, the (neutrophil + monocyte) / lymphocyte ratio (NMLR) may comprehensively reflect the inflammatory and immune status of the body. However, few studies have examined the association between the NMLR and all-cause mortality in patients with COPD. Objective The purpose of this study is to explore the relationship between NMLR and all-cause death in patients with COPD. Method Data from the National Health and Nutrition Examination Survey (NHANES) 1999–2018 with mortality follow-up through to December 31, 2019 were analyzed. A total of 2045 participants were evaluated. Patients were divided into two groups based on their median NMLR: patients with an NMLR ≤ 2.57 were assigned to the T1 group (n = 1,026), while patients with an NMLR > 2.57 were assigned to the T2 group (n = 1,019). The relationship between the NMLR and all-cause mortality in patients with COPD was assessed using survival curves based on the NHANES recommended weights. Conclusions The NMLR is a comprehensive assessment index of airway inflammation and patient immune status. A higher NMLR in patients with COPD is associated with a higher risk of all-cause mortality.

show abstract

Section: Introductionmentioning

confidence: 99%

WITHDRAWN: Relationship between NMLR and all-cause mortality in patients with chronic obstructive pulmonary disease: National Health and Nutrition Examination Survey, 1999–2018

Lü

Zhu

Xiao

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…28 Macrophages also produce an elastolytic inflammatory response and increased levels of matrix metalloproteinases, resulting in damage to lung tissue. 25,28 In addition, macrophages are unable to mount an adequate phagocytic response, which may result in impaired clearance of bacteria, in microbial dysbiosis, and, subsequently, in persistent inflammation. 25 Similarly, neutrophil numbers are increased in the airway lumen, and in COPD, neutrophils exhibit increased migration and induce mucus hypersecretion.…”

Section: Symposium Reviewmentioning

confidence: 99%

“…25,28 In addition, macrophages are unable to mount an adequate phagocytic response, which may result in impaired clearance of bacteria, in microbial dysbiosis, and, subsequently, in persistent inflammation. 25 Similarly, neutrophil numbers are increased in the airway lumen, and in COPD, neutrophils exhibit increased migration and induce mucus hypersecretion. 25,28 Christenson also highlighted the different molecular phenotypes in COPD and polarised adaptive immune responses.…”

Section: Symposium Reviewmentioning

confidence: 99%

“…25 Similarly, neutrophil numbers are increased in the airway lumen, and in COPD, neutrophils exhibit increased migration and induce mucus hypersecretion. 25,28 Christenson also highlighted the different molecular phenotypes in COPD and polarised adaptive immune responses. In stable obstructive disease, she noted that there are type 2-high, type 1-high, and type 17-high phenotypes.…”

Section: Symposium Reviewmentioning

confidence: 99%

See 1 more Smart Citation

New Frontiers in Chronic Obstructive Pulmonary Disease: Where Are We Heading?

et al. 2022

View full text Add to dashboard Cite

This symposium took place during the 2022 meeting of the European Respiratory Society (ERS). Focusing on new frontiers in chronic obstructive pulmonary disease (COPD), the speakers discussed the current understanding of the heterogeneity of COPD, the spectrum of inflammatory pathways in COPD pathophysiology, and the evolving clinical landscape in COPD. Alvar Agustí, Professor of Medicine at the University of Barcelona, Spain, introduced the concept of a gene, environment, and time (GETomic) perspective of COPD, ending with the trajectome, or range of lung function trajectories, through the lifespan. Stephanie Christenson, Assistant Professor of Pulmonology at the University of California, San Francisco, USA, followed by exploring the role of inflammation in COPD, highlighting that it is a heterogeneous disease with broad inflammatory pathways. This includes types 1, 17, and 2 inflammation; a wide range of immune effector cells beyond eosinophils; and key cytokines such as IL-33, IL-4, IL-13, and IL-5, which mediate the pathophysiology of COPD in response to cigarette smoke and other environmental insults. The need for continued investigation of molecular phenotypes was expanded on further by MeiLan Han, Professor of Medicine at the University of Michigan, Ann Arbor, USA, who explored the knowns and unknowns in the standard-of-care management of patients with COPD, highlighting the evolving understanding and identification of disease endotypes and phenotypes; poor understanding of COPD disease progression; the importance of smoking status in response to currently available treatments; and significant unmet need for additional treatment, even among patients on triple therapy. Dave Singh, Professor of Respiratory Pharmacology at the University of Manchester, UK, then discussed active areas of investigation in the development of additional treatments for patients with COPD.

show abstract

“…According to modern concepts, COPD is a disease whose pathophysiological basis is chronic airway inflammation, which develops in response to long-term exposure to tobacco smoke components [ 22 , 23 ]. Many cells involved in this inflammation, including macrophages and neutrophils, are part of the innate immune defense of the lungs [ 24 , 25 , 26 ]. The mechanisms of the innate immune system have been shown to be impaired in smoking and COPD [ 27 ].…”

Section: Introductionmentioning

confidence: 99%

High-Density Lipoproteins: A Role in Inflammation in COPD

Kotlyarov

2022

IJMS

Self Cite

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is a widespread disease associated with high rates of disability and mortality. COPD is characterized by chronic inflammation in the bronchi as well as systemic inflammation, which contributes significantly to the clinically heterogeneous course of the disease. Lipid metabolism disorders are common in COPD, being a part of its pathogenesis. High-density lipoproteins (HDLs) are not only involved in lipid metabolism, but are also part of the organism’s immune and antioxidant defense. In addition, HDL is a versatile transport system for endogenous regulatory agents and is also involved in the removal of exogenous substances such as lipopolysaccharide. These functions, as well as information about lipoprotein metabolism disorders in COPD, allow a broader assessment of their role in the pathogenesis of heterogeneous and comorbid course of the disease.

show abstract

Involvement of the Innate Immune System in the Pathogenesis of Chronic Obstructive Pulmonary Disease

Cited by 22 publications

References 190 publications

WITHDRAWN: Relationship between NMLR and all-cause mortality in patients with chronic obstructive pulmonary disease: National Health and Nutrition Examination Survey, 1999–2018

WITHDRAWN: Relationship between NMLR and all-cause mortality in patients with chronic obstructive pulmonary disease: National Health and Nutrition Examination Survey, 1999–2018

New Frontiers in Chronic Obstructive Pulmonary Disease: Where Are We Heading?

High-Density Lipoproteins: A Role in Inflammation in COPD

Contact Info

Product

Resources

About